Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Anorexia

Aetiology, Epidemiology and Management in Older People

  • 477 Accesses

  • 23 Citations

Abstract

The loss of appetite is termed ‘anorexia’. Dramatic and poorly understood alterations occur in the physiological regulation of appetite in older adults, who frequently exhibit less hunger and earlier satiety. Appetite regulation (and, therefore, food intake) is affected by a number of social, cultural and psychological factors, as well as by acute and chronic disease states, drugs, dementia or mood disorders. Self-reported anorexia has been reported by approximately one-third of older men and women. Recent development of validated measures of appetite aid in the approach to the problem. The differential diagnostic approach for appetite disturbances should follow from an understanding of the physiological, social, psychological and pathophysiological causes of anorexia. Emerging understanding of the association between proinflammatory cytokines and the anorexia/cachexia syndrome indicates that this process is the most commonly encountered underlying reason for anorexia in acute and chronically ill older persons. Despite the changes in appetite regulation in older persons, the response to social and psychological stimulants in this age group is similar to that in younger adults. Pharmacological stimulants of appetite appear to be a promising intervention for anorexia.

This is a preview of subscription content, log in to check access.

Table I
Table II
Table III
Fig. 1
Table IV
Table V

References

  1. 1.

    Murden RA, Ainslie NK. Recent weight loss is related to short-term mortality in nursing homes. J Gen Intern Med 1994; 9(11): 648–50

  2. 2.

    Weinsier RL, Hunker EM, Krumdieck CL, et al. Hospital malnutrition: a prospective evaluation of general medical patients during the course of hospitalization. Am J Clin Nutr 1979; 32(2): 418–26

  3. 3.

    Morley JE, Thomas DR. Anorexia and aging: pathophysiology. Nutrition 1999; 15(6): 499–503

  4. 4.

    Morley JE. Decreased food intake with aging. J Gerontol A Biol Sci Med Sci 2001; 56: 81–8

  5. 5.

    Roberts SB, Fuss P, Heyman MB, et al. Control of food intake in older men. JAMA 1994; 272: 1601–6

  6. 6.

    Morley JE. Anorexia, sarcopenia, and aging. Nutrition 2001; 17: 660–3

  7. 7.

    Morley JE. Anorexia in older persons: epidemiology and optimal treatment. Drugs Aging 1996; 8(2): 134–55

  8. 8.

    McGandy RB, Barrows Jr CH, Spanias A, et al. Nutrient intake and energy expenditure in men of different ages. J Gerontology 1966; 21: 581–7

  9. 9.

    Ritchie CR, Thomas DR. Aging. In: Heimburger DC, Weinsier RL, editors. Handbook of clinical nutrition. 3rd ed. St Louis (MO): Mosby, 1997

  10. 10.

    Abraham S, Carroll MD, Dresser CM, et al. Dietary intake of persons 1–74 years of age in the United States. Advance data from Vital and Health Statistics of the National Center for Health Statistics no. G. Rockville (MD): Public Health Service, 1977 Mar 30

  11. 11.

    De Castro JM. How can eating behavior be regulated in the complex environments of free-living humans? Neurosci Biobehav Rev 1996; 20: 119–31

  12. 12.

    Thomas DR. Unintended weight loss in older adults. Aging Health 2008; 4(2): 191–200

  13. 13.

    Thomas DR. Nutritional requirements in older adults. Chapter 6. In: Morley JE, Thomas DR, editors. Geriatric nutrition. Boca Raton (FL): CRC Press, 2007: 131–6

  14. 14.

    Doty RL, Shaman P, Applebaum SL, et al. Smell identification ability: changes with age. Science 1984; 226: 1441–3

  15. 15.

    Schiffman S. Food recognition by the elderly. J Gerontol 1977; 32: 586–92

  16. 16.

    Buckler DA, Kelber ST, Goodwin JS. The use of dietary restrictions in malnourished nursing home patients. J Am Geriatr Soc 1994; 42: 1100–2

  17. 17.

    Tariq S, Karcic E, Thomas DR, et al. The use of a no-concentrated-sweets diet in the management of type 2 diabetes in nursing home patients. J Am Diet Assoc 2001; 101(12): 1463–6

  18. 18.

    Morley JE, Silver AJ. Anorexia in the elderly. Neurobiol Aging 1988; 9: 9–16

  19. 19.

    Morley JE. Decreased food intake with aging. J Gerontol A Biol Sci Med Sci 2002; 57(1): M2–6

  20. 20.

    Donini LM, Savina C, Cannella C. Eating habits and appetite control in the elderly: the anorexia of aging. Int Psychogeriatr 2003; 15: 73–87

  21. 21.

    Hotaling DL. Nutritional considerations for the pureed diet texture in dysphagic elderly. Dysphagia 1992; 7: 81–5

  22. 22.

    Johnson RM, Smiciklas-Wright H, Soucy IM, et al. Nutrient intake of nursing home residents receiving pureed foods or a regular diet. J Am Geriatr Soc 1995; 43: 344–8

  23. 23.

    Kayser-Jones J. Mealtime in nursing homes: the importance of individualized care. J Gerontol Nurs 1996; 22: 26–31

  24. 24.

    Fitten LJ, Morley JE, Gross PI, et al. Depression. J Am Geriatr Soc 1989; 37(5): 459–72

  25. 25.

    Blaum CS, Fries BE, Fiatarone MA. Factors associated with low body mass index and weight loss in nursing home residents. J Gerontol 1995; 50:M162–8

  26. 26.

    Kaye WH, Klump KL, Frank GKW, et al. Anorexia and bulimia nervosa. Annu Rev Med 2000; 51: 299–313

  27. 27.

    Plata-Salaman CR. Anorexia during acute and chronic disease. Nutrition 1996; 12(2): 69–78

  28. 28.

    Hedlund J, Hansson LO, Ortqvist A. Short- and long-term prognosis for middle-aged and elderly patients hospitalized with community-acquired pneumonia: impact of nutritional and inflammatory factors. Scand J Infect Dis 1995; 27(1): 32–7

  29. 29.

    Plata-Salaman CR. Anorexia during acute and chronic disease. Nutrition 1996; 12: 69–76

  30. 30.

    Mowe M, Bohmer T, Kindt E. Reduced nutritional status in an elderly population (>70y) is probable before disease and possibly contributes to the development of disease. Am J Clin Nutr 1994; 59(2): 317–24

  31. 31.

    Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. Clin Nutr 2008; 27(6): 793–9

  32. 32.

    Baumgartner RN, Waters DL, Gallagher D, et al. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev 1999; 107: 123–36

  33. 33.

    Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998; 147: 755–63

  34. 34.

    Seruga B, Zhang H, Bernstein LJ, et al. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 2008; 8(11): 887–99

  35. 35.

    Laviano A, Meguid MM, Rossi-Fanelli F. Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies. Lancet Oncol 2003; 4: 686–94

  36. 36.

    Illman J, Corringham R, Robinson Jr D, et al. Are inflammatory cytokines the common link between cancer-associated cachexia and depression? J Support Oncol 2005; 3: 37–50

  37. 37.

    Rote NS. Inflammation. In: McCance KL, Huether SE, editors. Pathophysiology: the biological basis for disease in adults and children. St Louis (MO): Mosby, 1998: 205–36

  38. 38.

    Plata-Salaman CR. Strategies for potential manipulation of anorexia during acute and chronic disease. Nutrition 1995; 11:702–4

  39. 39.

    Espat NJ, Moldawer LL, Copeland 3rd EM. Cytokine-mediated alterations in host metabolism prevent nutritional repletion in cachectic cancer patients. J Surg Oncol 1995; 58: 77–82

  40. 40.

    Thomas DR. Loss of skeletal muscle mass in aging: examining the relationship of starvation, sarcopenia and cachexia. Clin Nutr 2007; 26(4): 389–99

  41. 41.

    Westerblad H, Allen DG. Recent advances in the understanding of skeletal muscle fatigue. Curr Opin Rheumatol 2002; 14(6): 648–52

  42. 42.

    Mitch WE. Mechanisms causing loss of lean body mass in kidney disease. Am J Clin Nutr 1998; 67: 359–66

  43. 43.

    Toth MJ, Gottlieb SS, Goran MI, et al. Daily energy expenditure in free-living heart failure patients. Am J Physiol 1997; 272: 469–75

  44. 44.

    Roubenoff R, Roubenoff RA, Cannon JG, et al. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest 1994; 93: 2379–86

  45. 45.

    Kotler DP, Wang J, Pierson RN. Body composition studies in patients with the acquired immunodeficiency syndrome. Am J Clin Nutr 1985; 42: 1255–65

  46. 46.

    Donini LM, Savina C, Piredda M, et al. Senile anorexia in acute-ward and rehabilitation settings. J Nutr Health Aging 2008; 12(8): 511–7

  47. 47.

    Serra Prat M, Fernandez X, Ribo L, et al. Loss of appetite in elderly people in the community and its relationship with functional capacity. Med Clin (Barc) 2008; 130(14): 531–3

  48. 48.

    Milne AC, Potter J, Avenell A. Protein and energy supplementation in elderly people at risk from malnutrition. Cochrane Database Syst Rev 2002; (3): CD003288

  49. 49.

    Lauque S, Arnaud-Battandier F, Mansourian R, et al. Protein-energy oral supplementation in malnourished nursing-home residents: a controlled trial. Age Aging 2000; 29: 51–6

  50. 50.

    Guigoz Y, Vellas B. Assessing the nutritional status of the elderly: the Mini Nutritional Assessment as part of the geriatric evaluation. Nutr Rev 1998; 54: S59–65

  51. 51.

    Keller HH, McKenzie JD, Goy RE. Construct validation and test-retest reliability of the seniors in the community: risk evaluation for eating and nutrition questionnaire. J Gerontol A Biol Sci Med Sci 2001; 56: M552–8

  52. 52.

    Ribaudo JM, Cella D, Hahn EA, et al. Re-validation and shortening of the functional assessment of anorexia/cachexia therapy (FAACT) questionnaire. Qual Life Res 2001; 9: 1137–46

  53. 53.

    Thomas DR. Nutritional Assessment in long term care. Nutr Clin Pract 2008; 23: 383–7

  54. 54.

    Portenoy RK, Thaler HT, Kornblith AB, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 1994; 30A: 1326–36

  55. 55.

    Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom Assessment Scale. Cancer 2000; 88: 2164–71

  56. 56.

    Cella DF, VonRoenn J, Lloyd S, et al. The Bristol-Myers Anorexia/Cachexia Recovery Instrument (BACRI): a brief assessment of patients’ subjective response to treatment for anorexia/cachexia. Qual Life Res 1995; 4: 221–31

  57. 57.

    Mathey MF. Assessing appetite in Dutch elderly with the Appetite, Hunger and Sensory Perception (AHSP) questionnaire. J Nutr Health Aging 2001; 5: 22–8

  58. 58.

    Wilson MM, Thomas DR, Rubenstein LZ, et al. Appetite assessment: simple appetite questionnaire predicts weight loss in community-dwelling adults and nursing home residents. Am J Clin Nutr 2005; 82(5): 1074–81

  59. 59.

    Thomas DR. Management of protein-energy under-nutrition in older adults, chapter 16. In: Morley JE, Thomas DR, editors. Geriatric nutrition. Boca Raton (FL): CRC Press, 2007: 267–90

  60. 60.

    Thomas DR. Causes of protein-energy malnutrition. In: Seiler WO, Stähelin HB, editors. Malnutrition in the elderly. Darmstadt: Steinhopff Verlag, 1999: 59–68

  61. 61.

    Thomas DR, Ashmen W, Morley JE, et al. Nutritional management in long-term care: development of a clinical guideline. J Gerontol A Biol Sci Med Sci 2000; 55: M725–34

  62. 62.

    Wilson MM, Vaswani S, Liu D, et al. Prevalence and causes of undernutrition in medical outpatients. Am J Med 1998; 104: 56–63

  63. 63.

    Schiffman SS, Warwick ZS. Effect of flavor enhancement of foods for the elderly on nutritional status: food intake, biochemical indices, and anthropometric measures. Physiol Behav 1993; 53: 395–402

  64. 64.

    Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982–1983; 17: 37–49

  65. 65.

    Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000; 11S: 37–41

  66. 66.

    Gelenberg AJ, Laukes C, McGahuey C, et al. Mirtazapine substitution in SSRI-induced sexual dysfunction. J Clin Psychiatry 2000; 61: 356–60

  67. 67.

    Carpenter LL, Leon Z, Yasmin S, et al. Clinical experience with mirtazapine in the treatment of panic disorder. Ann Clin Psychiatry 1999; 11: 81–6

  68. 68.

    Carpenter LL, Jocic Z, Hall JM, et al. Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 1999; 60: 45–9

  69. 69.

    Gants R. Detection and correction of underweight problems in nursing home residents. J Gerontol Nurs 1997; 23: 26–31

  70. 70.

    Dawe D, Moore-Orr R. Long-intensity range of motion exercise: invaluable nursing care for elderly patients. J Adv Nurs 1995; 21: 675–81

  71. 71.

    Ruuskanen JM, Ruoppila I. Physical activity and physiologic well being among people 65–84 years. Age Ageing 1995; 24: 292–6

  72. 72.

    Fiatarone MA, Marks EC, Ryan ND, et al. High-intensity training in nonogenarians: effects on skeletal muscle. JAMA 1990; 263: 3029–34

  73. 73.

    Johnson LE, Dooley PA, Gleick JB. Oral nutritional supplement use in elderly nursing home patients. J Am Geriatr Soc 1993; 41: 947–52

  74. 74.

    Elmstahl S, Steen B. Hospital nutrition in geriatric long-term care medicine: II. Effects of dietary supplements. Age Ageing 1987; 16: 73–80

  75. 75.

    Wilson MM, Purushothaman R, Morley JE. Effect of liquid dietary supplements on energy intake in the elderly. Am J Clin Nutr 2002; 75(5): 944–7

  76. 76.

    Milne AC, Avenell A, Potter J. Meta-analysis: protein and energy supplementation in older people. Ann Intern Med 2006; 144(1): 37–48

  77. 77.

    Lauque S, Arnaud-Battandier F, Gillette S, et al. Improvement of weight and fat-free mass with oral nutritional supplementation in patients with Alzheimer’s disease at risk of malnutrition: a prospective randomized study. J Am Geriatr Soc 2004; 52(10): 1702–7

  78. 78.

    Thomas DR. Guidelines for the use of orexigenic drugs in longterm care. Nutr Clin Pract 2006; 21(1): 82–7

  79. 79.

    Moertel C, Schutt AG, Reiteneier RJ, et al. Corticosteroid therapy of pre-terminal gastrointestinal cancer. Cancer 1974; 33: 1607–9

  80. 80.

    Willox J, Corr J, Shaw J, et al. Prednisolone as an appetite stimulant in patients with cancer. Br Med J (Clin Res Ed) 1984; 288(6410): 27

  81. 81.

    Bruera E, Roca E, Cedaro L, et al. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double blind study. Cancer Treat Rep 1985; 69: 751–4

  82. 82.

    Robusteli Della Cuna G, Pellegrini A, Piazzi M. Effect of methylprednisolone sodium succinate on quality of life in pre-terminal cancer patients: a placebo controlled multicenter study. Eur J Cancer Clin Oncol 1989; 25: 1823–9

  83. 83.

    Popiela T, Lucchi R, Giongo F. Methylprednisolone as palliative therapy for female terminal cancer patients. Eur J Cancer Clin Oncol 1989; 25: 1823–4

  84. 84.

    Nelson K, Walsh D, Deeter P, et al. A phase II study of delta-nine-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care 1994; 10: 14–8

  85. 85.

    Kardinal C, Loprinzi CL, Schaid DJ, et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 1990; 65: 2657–62

  86. 86.

    Tchekmedyian S, Tait N, Moody M, et al. High dose megestrol acetate: a possible treatment of cachexia. JAMA 1987; 257: 1195–9

  87. 87.

    Cruz JM, Muss HB, Brockschmidt JK, et al. Weight changes in women with metastatic breast cancer treated with megestrol acetate: a comparison of standard vs. a high does therapy. Semin Oncol 1990; 17 Suppl.: 63–7

  88. 88.

    Bruerra E, Macmillan K, Hanson J, et al. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 1990; 66: 1279–82

  89. 89.

    Loprinzi CL, Ellison NM, Schaid DJ, et al. Controlled trial of megestrol acetate for the treatment of cancer, anorexia and cachexia. J Natl Cancer Inst 1990; 82: 1127–32

  90. 90.

    Schmoll E, Wilke H, Thole R. Megestrol acetate in cancer cachexia. Semin Oncol 1991; 1Suppl. 2: 32–4

  91. 91.

    Heckmayr M, Gatzenneier U. Treatment of cancer weight loss in patients with advanced lung cancer. Oncology 1992; 49Suppl. 2: 32–4

  92. 92.

    Feliu J, Gonzalez-Baron M, Berrocal A. Usefulness of megestrol acetate in cancer cachexia and anorexia. Am J Clin Oncol 1992; 15: 436–40

  93. 93.

    Azona C, Castro L, Crespo E, et al. Megestrol acetate therapy for anorexia and weight loss in children with malignant solid tumors. Aliment Pharmacol Ther 1996; 10(4): 577–86

  94. 94.

    Mantovani G, Maccio A, Bianchi A, et al. Megestrol acetate in neoplastic anorexia/cachexia: clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy. Int J Clin Lab Res 1995; 25: 135–41

  95. 95.

    Tchekmedyian S, Hakman M, Siau J, et al. Megestrol acetate in cancer anorexia and weight loss. Cancer 1992; 69: 1268–74

  96. 96.

    Beller E, Tattersail M, Lumley T, et al. Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: a randomized placebo-control trial. Ann Oncol 1997; 8: 277–83

  97. 97.

    Bruera E, Ernst S, Hagen N, et al. Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study. Cancer Prev Control 1998; 2(2): 74–8

  98. 98.

    Fietkau R, Riepl M, Kettner H. Supportive use of megestrol acetate in patients with head and neck cancer during radio (chemo)therapy. Eur J Cancer 1997; 33: 75–9

  99. 99.

    McMillan DC, Wigmore SJ, Fearon KC, et al. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 1999; 79: 495–500

  100. 100.

    Gebbia V, Testa A, Gebbia N. Prospective randomized trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer. Br J Cancer 1996; 73(12): 1576–80

  101. 101.

    Plassee TF, Gorter RW, Krasnow SH, et al. Recent clinical experience with dronabinol. Pharmacol Biochem Behav 1991; 40: 695–700

  102. 102.

    Beal JE, Olson R, Lefkowitz L, et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 1997; 14: 7–14

  103. 103.

    Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group Study. J Clin Oncol 1002; 20: 567–73

  104. 104.

    Volicer L, Stelly M, Morris J, et al. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 1997; 12: 913–9

  105. 105.

    Gonzalez-Rosales F, Walsh D. Intractable nausea and vomiting due to gastrointestinal mucosal metastases relieved by tetrahydrocannabinol (dronabinol). J Pain Symptom Manage 1997; 14: 311–4

  106. 106.

    Reyes-Teran G, Sieira-Madero JG, Martinez Del Cerro V, et al. Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS 1996; 10: 1501–7

  107. 107.

    Standards options and recommendations for the use of appetite stimulants in oncology. Work group. Federation of the French Cancer Centres (FNCLCC). Bull Cancer 2000; 87: 315–28

  108. 108.

    Jatoi A, Rowland K, Loprinzi CL, et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol 2004; 22: 2469–76

  109. 109.

    Morley JE, Kaiser FE, Perry HM, et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997; 46: 410–3

  110. 110.

    Morley JE, Distiller LA, Lissoos I, et al. Testicular function in patients with spinal cord damage. Horm Metab Res 1979; 11:679–82

  111. 111.

    Rudman D, Mattson DE, Nagraj HS, et al. Plasma testosterone in nursing home men. J Clin Epidemiol 1988; 41: 231–6

  112. 112.

    Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 2670–7

  113. 113.

    Morley JE, Perry 3rd HM, Kaiser FE, et al. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993; 41: 149–52

  114. 114.

    Sih R, Morley JE, Kaiser FE, et al. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997; 82: 1661–7

  115. 115.

    Borst SE, Mulligan T. Testosterone replacement therapy for older men. Clin Interv Aging 2007; 2(4): 561–6

  116. 116.

    Hengge UR, Baumann M, Maleba R, et al. Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection. Br J Nutr 1996; 75(1): 129–38

  117. 117.

    Pengelly CD. Oxymetholone in the chemotherapy of malignant disease. Curr Med Res Opin 1973; 1(7): 401–6

  118. 118.

    Schambelan M, Mulligan K, Grunfeld C, et al. Recombinant human growth hormone in patients with HIV-associated wasting: a randomized, placebo-controlled trial. Ann Intern Med 1996; 125: 873–82

  119. 119.

    Kaiser FE, Silver AJ, Morley JE. The effect of recombinant human growth hormone on malnourished older individuals. J Am Geriatr Soc 1991; 39: 235–40

  120. 120.

    Takala J, Ruokonen E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999; 341: 785–92

  121. 121.

    Deans C, Wigmore SJ. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metabol Care 2005; 8: 265–9

  122. 122.

    Yeh SS, Wu SY, Levine DM, et al. The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. J Gerontol A Biol Sci Med Sci 2001; 56: M48–54

  123. 123.

    Yeh SS, Hafner A, Schuster MW, et al. Relationship between body composition and cytokines in cachectic patients with chronic obstructive pulmonary disease. J Am Geriatr Soc 2003; 51: 1365–2389

  124. 124.

    Gordon JN, Trebble TM, Ellis RD, et al. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 2005; 54: 540–5

  125. 125.

    Fearon KC, Von Meyenfeldt MF, Moses AG, et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 2003; 52: 1479–86

  126. 126.

    Yarasheski KE. Growth hormone effects on metabolism, body composition, muscle mass, and strength. Exerc Sport Sci Rev 1994; 22: 285–312

  127. 127.

    Berenstein EG, Ortiz Z. Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2005 Apr 18; (2): CD004310

  128. 128.

    Loprinzi C, Jensen M, Jiang N, et al. Effect of megestrol acetate on the human pituitary-adrenal axis. Mayo Clin Proc 1992; 67: 1160–2

  129. 129.

    Koller E, Gibert C, Green L, et al. Thrombotic events associated with megestrol acetate in patients with AIDS cachexia. Nutrition 1999; 15: 294–8

  130. 130.

    Thomas DR. Incidence of venous thromboembolism in megestrol acetate users. J Am Med Dir Assoc 2004; 5: 65–7

  131. 131.

    Hansson PO, Welin L, Tibblin G, et al. Deep vein thrombosis and pulmonary embolism in the general population. Arch Intern Med 1997; 157: 1665–70

  132. 132.

    Kniffin Jr WD, Baron JA, Barrett J, et al. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 1992; 232: 155–60

  133. 133.

    Spitzer WO, Lewis MA, Heinemann LA, et al. Third generation oral contraceptives and risk of venous thrombotic disorders: an international case control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996; 312(7023): 83–8

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The author has no conflicts of interest that are directly relevant to the content of this review.

Author information

Correspondence to Dr David R. Thomas.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Thomas, D.R. Anorexia. Drugs Aging 26, 557–570 (2009). https://doi.org/10.2165/11316360-000000000-00000

Download citation

Keywords

  • Anorexia Nervosa
  • Carpal Tunnel Syndrome
  • Megestrol
  • Percentage Weight Gain
  • Nabilone